Presence of 1q gain and absence of 7p gain are new predictors of local or metastatic relapse in localized resectable neuroblastoma

Neuro-Oncology

Volumn 11, Issue 2, 2009, Pages 192-200

  Pezzolo, Annalisa ^a   Rossi, Elena ^b   Gimelli, Stefania ^b   Parodi, Federica ^a   Negri, Francesca ^a   Conte, Massimo ^a   Pistorio, Angela ^a   Sementa, Angela ^a   Pistoia, Vito ^a   Zuffardi, Orsetta ^b   Gambini, Claudio ^a  

^a G GASLINI INSTITUTE   (Italy)

^b UNIVERSITY OF PAVIA   (Italy)

Author keywords

1q gain; 7p gain; Array cgh; Localized resectable neuroblastoma; Prognostic markers

Indexed keywords

ARTICLE; CANCER CHEMOTHERAPY; CANCER GROWTH; CANCER RECURRENCE; CANCER REGRESSION; CANCER RELAPSE; CANCER RISK; CANCER STAGING; CANCER SURGERY; CANCER SURVIVAL; CHILD; CHROMOSOME 17Q; CHROMOSOME 1P; CHROMOSOME 1Q; CHROMOSOME 22P; CHROMOSOME 3P; CHROMOSOME 7P; CHROMOSOME DELETION; CLINICAL ARTICLE; COMPARATIVE GENOMIC HYBRIDIZATION; CONTROLLED STUDY; FEMALE; FOLLOW UP; GENE FREQUENCY; GENETIC GAIN; GENETIC PREDISPOSITION; HUMAN; MALE; METASTASIS; NEUROBLASTOMA; PRESCHOOL CHILD; SCHOOL CHILD;

CHILD; CHILD, PRESCHOOL; CHROMOSOME ABERRATIONS; CHROMOSOMES, HUMAN, PAIR 1; CHROMOSOMES, HUMAN, PAIR 7; COMPARATIVE GENOMIC HYBRIDIZATION; DNA, NEOPLASM; FEMALE; GENE EXPRESSION PROFILING; HUMANS; IN SITU HYBRIDIZATION, FLUORESCENCE; INFANT; KARYOTYPING; MALE; NEOPLASM RECURRENCE, LOCAL; NEUROBLASTOMA; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; PROGNOSIS; SURVIVAL RATE; TREATMENT OUTCOME;

EID: 65949100780     PISSN: 15228517     EISSN: 15235866     Source Type: Journal    
DOI: 10.1215/15228517-2008-086     Document Type: Article

References (48)

1. Maris JM. The biologic basis for neuroblastoma heterogeneity and risk stratification. Curr Opin Pediatr. 2005;17:7-13.
2. Breslow N, McCann B. Statistical estimation of prognosis for children with neuroblastoma. Cancer Res. 1971;31:2098-2103.
3. Brodeur GM, Pritchard J, Berthold F, et al. Revisions of the interna- tional criteria for neuroblastoma diagnosis, staging, and response to treatment. J Clin Oncol. 1993;11:1466-1477.
4. Shimada H, Ambros IM, Dehner LP, et al. The International Neuro- blastoma Pathology Classification (the Shimada system). Cancer. 1999;86:364-372.
5. Look AT, Hayes FA, Shuster JJ, et al. Clinical relevance of tumor cell ploidy and MYCN gene amplification in childhood neuroblastoma: a pediatric oncology group study. J Clin Oncol. 1991;9:581-591.
6. Seeger RC, Brodeur GM, Sather H, et al. Association of multiple copies of the MYCN oncogene with rapid progression of neuroblastomas. N Engl J Med. 1985;313:1111-1116.
7. Schwab M, Alitalo K, Klempnauer KH, et al. Amplified DNA with limited homology to myc cellular oncogene is shared by human neuroblastoma cell lines and a neuroblastoma tumor. Nature. 1983;305:245-248.
8. Brodeur GM, Seeger RC, Schwab M, et al. Amplification of N-myc in untreated human neuroblastoma correlates with advanced disease stage. Science. 1984;224:1121-1124.
9. Brodeur GM. Neuroblastoma: biological insights into a clinical enigma. Nat Rev Cancer. 2003;3:203-216.
10. Navarro S, Amann G, Beiske K, et al. Prognostic value of interna- tional neuroblastoma pathology classification in localized resectable peripheral neuroblastic tumors: a histopathologic study of localized neuroblastoma European Study Group 94.01 trial and protocol. J Clin Oncol. 2006;24:695-699.
11. Berthold F, Hero B, Breu H, et al. The recurrence patterns of stage I, II and III neuroblastoma: experience with 77 relapsing patients. Ann Oncol. 1996;7:183-187.
12. Nitschke R, Smith EI, Shochat S, et al. Localized neuroblastoma treated by surgery. A Pediatric Oncology Group study. J Clin Oncol. 1988;6:1271-1279.
13. Matthay KK, Sather HN, Seeger RC, et al. Excellent outcome of stage II neuroblastoma is independent of residual disease and radiation therapy. J Clin Oncol. 1989;7:236-244.
14. Perez CA, Matthay KK, Atkinson JB, et al. Biologic variables in the out- come of stage I and II neuroblastoma treated with surgery as primary therapy: a children's cancer group study. J Clin Oncol. 2000;18:18-26.
15. Kallioniemi A, Kallioniemi OP, Sudar D, et al. Comparative genomic hybridization for molecular cytogenetics analysis of solid tumors. Sci- ence. 1992;258:818-821.
16. Lucito R, Healy J, Alexander J, et al. Representational oligonucleotide microarray analysis: a high-resolution method to detect genome copy number variation. Genome Res. 2003;13:2291-2205.
17. London WB, Boni L, Simon T, et al. The role of age in neuroblastoma risk stratification: the German, Italian, and Children's Oncology Group perspectives. Cancer Lett. 2005;228:257-266.
18. London WB, Castleberry RP, Matthay KK, et al. Evidence for an age cutoff greater than 365 days for neuroblastoma risk group stratifica- tion in the Children's Oncology Group. J Clin Oncol. 2005;23:6459-6465.
19. Ladenstein R, Ambros IM, Pötschger U, et al. Prognostic signifi- cance of DNA di-tetraploidy in neuroblastoma. Med Pediatr Oncol. 2001;36:83-92.
20. Spitz R, Hero B, Ernestus K, et al. Deletions in chromosome arms 3p and 11q are new prognostic markers in localized and 4s neuroblas- toma. Clin Cancer Res. 2003;9:52-58.
21. Spitz R, Hero B, Simon T, Berthold F. Loss in chromosome 11q identi- fies tumors with increased risk for metastatic relapses in localized and 4S neuroblastoma. Clin Cancer Res. 2006;12:3368-3373.
22. Simon T, Spitz R, Hero B, et al. Risk estimation in localized unresect- able single copy MYCN neuroblastoma by the status of chromosomes 1p and 11q. Cancer Lett. 2006;237:215-222.
23. Bown N, Cotterill S, Lastowska M, et al. Gain of chromosome arm 17q and adverse outcome in patients with neuroblastoma. N Engl J Med. 1999;340:1954-1961.
24. Caron H, van Sluis P, de Kraker J, et al. Allelic loss of chromosome 1p as a predictor of unfavorable outcome in patients with neuroblas- toma. N Engl J Med. 1996;334:225-230.
25. Maris JM, Weiss MJ, Guo C, et al. Loss of heterozygosity at 1p36 inde- pendently predicts for disease progression but not decreased over- all survival probability in neuroblastoma patients: a children's cancer group study. J Clin Oncol. 2000;18:1888-1899.
26. Spitz R, Hero B, Westermann F, et al. Fluorescence in situ hybridiza- tion analyses of chromosome band 1p36 in neuroblastoma detect two classes of alterations. Genes Chrom Cancer. 2002;34:299-305.
27. Vasudevan SA, Russell HV, Okcu MA, et al. Neuroblastoma-derived secretory protein messenger RNA levels correlate with high-risk neu- roblastoma. J Pediat Surg. 2007;42:148-152.
28. Laureys G, Speleman F, Opdenakker G, et al. Constitutional translo- cation t(1;17)(p36;q12-21) in a patient with neuroblastoma. Genes Chrom Cancer. 1990;2:252-254.
29. Vandepoele K, Van Roy N, Staes K, et al. A novel gene family NBPF: intricate structure generated by gene duplications during primate evo- lution. Mol Biol Evol. 2005;22(11):2265-2274.
30. Greco A, Mariani C, Miranda C, et al. Characterization of the NTRK1 genomic region involved in chromosomal rearrangements generating TRK oncogenes. Genomics. 1993;18:397-400.
31. Miozzo M, Pierotti M, Sozzi G, et al. Human TRK proto-oncogene maps to chromosome 1q32-q41. Oncogene. 1990;5:1411-1414.
32. Almeida A, Zhu XX, Vogt N, et al. GAC1, a new member of the leucine- rich repeat superfamily on chromosome band 1q32.1, is amplified and overexpressed in malignant gliomas. Oncogene. 1998;16:2997-3002.
33. Nakamura H, Izumoto Y, Kambe H, et al. Molecular cloning of com- plementary DNA for a novel human hepatoma-derived growth fac- tor: its homology with high mobility group-1 protein. J Biol Chem. 1994;269:25143-25149.
34. Russo VC, Schütt BS, Andaloro E, et al. Insulin-like growth factor binding protein-2 binding to extracellular matrix plays a critical role in neuroblastoma cell proliferation, migration, and invasion. Endocrinol- ogy. 2005;146:4445-4455.
35. Ehrenborg E, Larsson C, Stern I, et al. Contiguous localization of the genes encoding human insulin-like growth factor-binding proteins 1 (IGBP1) and 3 (IGBP3) on chromosome 7. Genomics. 1992;12:497-502.
36. Spitz R, Oberthuer A, Zapatka M, et al. Oligonucleotide array-based comparative genomic hybridization (aCGH) of 90 neuroblastomas reveals aberration patterns closely associated with relapse pattern and outcome. Genes Chrom Cancer. 2006;45:1130-1142.
37. Vandesompele J, Bacolod M, Selvanayagam Z, et al. Unequivocal delineation of clinicogenetic subgroups and development of a new model for improved outcome prediction in neuroblastoma. J Clin Oncol. 2005;10:22280-22299.
38. White PS, Maris JM, Beltinger C, et al. A region of consistent dele- tion in neuroblastoma maps within human chromosome 1p36.2-36.3. Proc Natl Acad Sci USA. 1995;92:5520-5524.
39. Attiyeh EF, London WB, Mosse YP, et al. Chromosome 1p and 11q dele- tions and outcome in neuroblastoma. N Engl J Med. 2005;353:2243-2253.
40. Luttikhuis ME, Powell JE, Rees SA, et al. Neuroblastomas with chromo- some 11q loss and single copy MYCN comprise a biologically distinct group of tumors with adverse prognosis. Br J Cancer. 2001;85:531-537.
41. Caron H, van Sluis P, de Kraker J, et al. Allelic loss of chromosome 1p as a predictor of unfavorable outcome in patients with neuroblas- toma. N Engl J Med. 1996;334:225-230.
42. Chen QR, Bilke S, Wei JS, et al. cDNA array-CGH profiling identifies genomic alterations specific to stage and MYCN amplification in neu- roblastoma. BMC Genomics. 2004;5:70.
43. Schleiermacher G, Michon J, Huon I, et al. Chromosomal CGH identi- fies patients with a higher risk of relapse in neuroblastoma without MYCN amplification. Br J Cancer. 2007;97:238-246.
44. Bagchi A, Papazoglu C, Wu Y, et al. CHD5 is a tumor suppressor at human 1p36. Cell. 2007;128:459-475.
45. White PS, Thompson PM, Gotoh T, et al. Definition and character- ization of a region of 1p36.3 consistently deleted in neuroblastoma. Oncogene. 2005;24:2684-2694.
46. Okawa ER, Gotoh T, Manne J, et al. Expression and sequence analysis of candidates for the 1p36.31 tumor suppression gene deleted in neu- roblastomas. Oncogene. 2007;14:1-8.
47. Wang Q, Diskin S, Rappaport E, et al. Integrative genomics identifies distinct molecular classes of neuroblastoma and shows that multiple genes are targeted by regional alterations in DNA copy number. Can- cer Res. 2006;66:6050-6062.
48. Mosse YP, Diskin SJ, Wasserman N, et al. Neuroblastomas have distinct genomic DNA profiles that predict clinical phenotype and regional gene expression. Genes Chrom Cancer. 2007;46:936-949.